

Resource Summary Report

Generated by [NIF](#) on Jul 31, 2026

Mouse Anti-Cytokeratin, pan Monoclonal Antibody, Unconjugated, Clone C-11

RRID:AB_306047

Type: Antibody

Proper Citation

Abcam Cat# ab7753, RRID:AB_306047

Antibody Information

URL: http://antibodyregistry.org/AB_306047

Proper Citation: Abcam Cat# ab7753, RRID:AB_306047

Target Antigen: pan Cytokeratin

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Immunocytochemistry; Immunohistochemistry; Immunoprecipitation; Western Blot; Immunocytochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-P, Immunoprecipitation, Western Blot

Antibody Name: Mouse Anti-Cytokeratin, pan Monoclonal Antibody, Unconjugated, Clone C-11

Description: This monoclonal targets pan Cytokeratin

Target Organism: all

Clone ID: Clone C-11

Antibody ID: AB_306047

Vendor: Abcam

Catalog Number: ab7753

Record Creation Time: 20250820T020951+0000

Record Last Update: 20250820T125126+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-Cytokeratin, pan Monoclonal Antibody, Unconjugated, Clone C-11.

No alerts have been found for Mouse Anti-Cytokeratin, pan Monoclonal Antibody, Unconjugated, Clone C-11.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 41 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zhang Y, et al. (2026) Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. *Cancer cell*, 44(1), 77.

Chen C, et al. (2026) B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity. *Cancer cell*.

Zeng L, et al. (2025) Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial. *Med (New York, N.Y.)*, 6(6), 100574.

Chang J, et al. (2025) Single-cell multi-stage spatial evolutionary map of esophageal carcinogenesis. *Cancer cell*, 43(3), 380.

Zhang Y, et al. (2025) Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance. *Cell*, 188(24), 6754.

Li G, et al. (2025) Microenvironmental ?-TrCP negates amino acid transport to trigger CD8+ T cell exhaustion in human non-small cell lung cancer. *Cell reports*, 44(1), 115128.

Nguyen DT, et al. (2025) Protein kinase C? dictates tumor trajectory, cell plasticity, and immune surveillance in lung adenocarcinoma. *Cell reports*, 44(12), 116606.

Lee MR, et al. (2025) Organoid morphology-guided classification for oral cancer reveals prognosis. *Cell reports. Medicine*, 6(5), 102129.

Tang R, et al. (2025) Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism. *Gastroenterology*, 169(4), 615.

Xu M, et al. (2025) Effects of anlotinib combined with camrelizumab and chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma on tumor immune microenvironment. *Journal of gastrointestinal oncology*, 16(4), 1366.

Song L, et al. (2025) Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLC. *iScience*, 28(9), 113211.

Dai D, et al. (2024) Chemoradiotherapy-induced ACKR2+ tumor cells drive CD8+ T cell senescence and cervical cancer recurrence. *Cell reports. Medicine*, 5(5), 101550.

Zhao J, et al. (2024) Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer. *Med (New York, N.Y.)*, 5(8), 981.

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway. *Cell genomics*, 4(10), 100659.

Gong C, et al. (2024) Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal/HER2-low breast cancer: PILHLE-001 study. *Cell reports. Medicine*, 5(11), 101807.

Miao N, et al. (2024) Tumor cell-intrinsic Piezo2 drives radioresistance by impairing CD8+ T cell stemness maintenance. *The Journal of experimental medicine*, 221(10).

Zheng C, et al. (2024) IFN γ -induced BST2+ tumor-associated macrophages facilitate immunosuppression and tumor growth in pancreatic cancer by ERK-CXCL7 signaling. *Cell reports*, 43(4), 114088.

Luo Y, et al. (2024) Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. *Cell*, 187(18), 4905.

Ning J, et al. (2024) Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation. *Cell reports. Medicine*, 5(5), 101505.

Yonemura A, et al. (2024) Mesothelial cells with mesenchymal features enhance peritoneal dissemination by forming a protumorigenic microenvironment. *Cell reports*, 43(1), 113613.